Pacira BioSciences Inc. (PCRX) Insider Trading

Last 12 months

Insiders sold $2.75M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Aug 2024.

Net open-market

−$2.75M

0 buys · 14 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Aug 2024

Aug 16, 2024

Get an email when PCRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 8	Lauren Riker Senior Vice President, Finance	Sold10b5-1 plan	6,000	$36.32	$218k	8.8%	Form 4
Aug 17	Jonathan Slonin Chief Medical Officer	Sold10b5-1 plan	3,040	$23.23	$71k	1.4%	Form 4
Jun 11	Lauren Riker Senior Vice President, Finance	Sold10b5-1 plan	6,115	$23.50	$144k	8.9%	Form 4
Jun 4	Kristen Williams Chief Administrative Officer	Sold10b5-1 plan	10,259	$22.27	$228k	5.8%	Form 4
Apr 23	Shawn Cross Chief Financial Officer	Sold10b5-1 plan	12,941	$25.16	$326k	11%	Form 4
Apr 20 – 22	Shawn Cross Chief Financial Officer	Sold10b5-1 plan 3 parts	12,059	$25.09 average	$303k	10%	Form 4
Mar 17	Jonathan Slonin Chief Medical Officer	Sold10b5-1 plan	3,261	$22.82	$74k	1.4%	Form 4
Mar 17	Mark Froimson Director	SoldNo plan	500	$21.81	$11k	2.4%	Form 4
Feb 2	Lauren Riker Senior Vice President, Finance	Sold10b5-1 plan	4,000	$20.81	$83k	7.1%	Form 4
Feb 2	Kristen Williams Chief Administrative Officer	Sold10b5-1 plan	13,137	$20.53	$270k	9.1%	Form 4
Jan 5	Lauren Riker Senior Vice President, Finance	Sold10b5-1 plan	1,416	$24.24	$34k	2.3%	Form 4
Dec 9, 2025 – Dec 10, 2025	Shawn Cross Chief Financial Officer	Sold10b5-1 plan 2 parts	25,000	$25.07 average	$627k	31%	Form 4
Nov 17, 2025	Jonathan Slonin Chief Medical Officer	Sold10b5-1 plan	3,960	$24.09	$95k	2.2%	Form 4
Nov 10, 2025	Shawn Cross Chief Financial Officer	Sold10b5-1 plan	12,060	$22.09	$266k	18%	Form 4
Sep 4, 2025	Abraham Ceesay Director	Sold10b5-1 plan	2,354	$27.19	$64k	21%	Form 4
Aug 7, 2025	Marcelo Bigal Director	SoldNo plan	4,912	$23.67	$116k	30%	Form 4
Jun 4, 2025	Lauren Riker Senior Vice President, Finance	SoldNo plan	5,578	$26.21	$146k	8.6%	Form 4
Jun 4, 2025	Kristen Williams Chief Administrative Officer	SoldNo plan	14,376	$26.24	$377k	8.2%	Form 4
Jan 6, 2025	Jonathan Slonin Chief Medical Officer	Sold10b5-1 plan	879	$18.40	$16k	0.9%	Form 4
Dec 13, 2024	Daryl Gaugler Chief Operating Officer	Sold10b5-1 plan	500	$19.76	$10k	0.4%	Form 4

Oct 810b5-1 plan
Lauren Riker
Senior Vice President, Finance · sold 6,000 at $36.32
$218k
8.8% of stake
Aug 1710b5-1 plan
Jonathan Slonin
Chief Medical Officer · sold 3,040 at $23.23
$71k
1.4% of stake
Jun 1110b5-1 plan
Lauren Riker
Senior Vice President, Finance · sold 6,115 at $23.50
$144k
8.9% of stake
Jun 410b5-1 plan
Kristen Williams
Chief Administrative Officer · sold 10,259 at $22.27
$228k
5.8% of stake
Apr 2310b5-1 plan
Shawn Cross
Chief Financial Officer · sold 12,941 at $25.16
$326k
11% of stake
Apr 20 – 2210b5-1 plan
Shawn Cross
Chief Financial Officer · sold 12,059 at avg $25.09
$303k
10% of stake
Mar 1710b5-1 plan
Jonathan Slonin
Chief Medical Officer · sold 3,261 at $22.82
$74k
1.4% of stake
Mar 17No plan
Mark Froimson
Director · sold 500 at $21.81
$11k
2.4% of stake
Feb 210b5-1 plan
Lauren Riker
Senior Vice President, Finance · sold 4,000 at $20.81
$83k
7.1% of stake
Feb 210b5-1 plan
Kristen Williams
Chief Administrative Officer · sold 13,137 at $20.53
$270k
9.1% of stake
Jan 510b5-1 plan
Lauren Riker
Senior Vice President, Finance · sold 1,416 at $24.24
$34k
2.3% of stake
Dec 9, 2025 – Dec 10, 202510b5-1 plan
Shawn Cross
Chief Financial Officer · sold 25,000 at avg $25.07
$627k
31% of stake
Nov 17, 202510b5-1 plan
Jonathan Slonin
Chief Medical Officer · sold 3,960 at $24.09
$95k
2.2% of stake
Nov 10, 202510b5-1 plan
Shawn Cross
Chief Financial Officer · sold 12,060 at $22.09
$266k
18% of stake
Sep 4, 202510b5-1 plan
Abraham Ceesay
Director · sold 2,354 at $27.19
$64k
21% of stake
Aug 7, 2025No plan
Marcelo Bigal
Director · sold 4,912 at $23.67
$116k
30% of stake
Jun 4, 2025No plan
Lauren Riker
Senior Vice President, Finance · sold 5,578 at $26.21
$146k
8.6% of stake
Jun 4, 2025No plan
Kristen Williams
Chief Administrative Officer · sold 14,376 at $26.24
$377k
8.2% of stake
Jan 6, 202510b5-1 plan
Jonathan Slonin
Chief Medical Officer · sold 879 at $18.40
$16k
0.9% of stake
Dec 13, 202410b5-1 plan
Daryl Gaugler
Chief Operating Officer · sold 500 at $19.76
$10k
0.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PCRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

KNSAKiniksa Pharmaceuticals International, plc

AMPHAmphastar Pharmaceuticals Inc.

EBSEmergent BioSolutions Inc.

RAREUltragenyx Pharmaceutical Inc.

AXSMAxsome Therapeutics, Inc.

BBIOBridgeBio Pharma, Inc.

TGTXTG Therapeutics, Inc.

COLLCollegium Pharmaceutical Inc.

Spot a number that looks wrong? Check it in PCRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PCRX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.